entertainment -WSS

entertainment

author：leisure time 2025-09-06 01:58:49 - browse：184

STAT's Casey Ross (left) and Kimberly Powell, NVIDIA's vice president for healthcare at the STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — In the world of drug discovery, AI progress is often measured by a single-mile marker: When will we get an AI-designed drug?

The answer remains, ambiguously, “the future,” but at STAT’s Breakthrough Summit leaders from NVIDIA and Google insisted that the impact of AI is visible today.

Kimberly Powell, vice president of healthcare for NVIDIA, pointed to an increase in investigational new drug applications filed with the Food and Drug Administration that cite AI, as well as an uptick in early-stage readouts from clinical trials, as evidence of progress. Some of the recent readouts, Powell said, show that what’s going into Phase 1 clinical trials is more successful.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： J&J lung cancer data amount to new salvo against AstraZeneca

WSS

J&J lung cancer data amount to new salvo against AstraZeneca

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

IVG is promising — but it won’t replace IVF quite yet

European officials brace for rough respiratory virus season

ADCs take center stage as promising cancer treatments

Experts study whether long Covid risk adds up with each reinfection

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Apple is now the first public company to be valued at $3 trillion

Congress extends some pandemic preparedness programs

Sports medicine is finally prioritizing gender equality

Will an HIV vaccine ever be a reality?

Jerome Adams on the need for new antivirals for Covid

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Apple is now the first public company to be valued at $3 trillion

Some top drug companies are starting to take action on climate

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Experts study whether long Covid risk adds up with each reinfection

leisure time

Study points to new risk in gene therapy death of Terry Horgan

Some top drug companies are starting to take action on climate

J&J lung cancer data amount to new salvo against AstraZeneca

Health tech investors get more selective as pandemic boom fades

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Questions loom on AstraZeneca cancer drug as safety concerns ebb

knowledge

hotspot

focus

knowledge